Urovant Sciences Ltd. (UROV) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
5281 CALIFORNIA AVENUE IRVINE, CA 92617 |
| State of Incorp. | |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2020 | 3/31/2019 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 85,353,000 | |||
| Cash and cash equivalents | 85,353,000 | |||
| Restricted cash and investments | 243,000 | |||
| Receivables | ||||
| Other undisclosed current assets | 12,914,000 | |||
| Total current assets: | 98,510,000 | |||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | ✕ | |||
| Property, plant and equipment | 923,000 | |||
| Restricted cash and investments | 600,000 | |||
| Other undisclosed noncurrent assets | 88,000 | |||
| Total noncurrent assets: | 1,611,000 | |||
| TOTAL ASSETS: | 100,121,000 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 11,802,000 | |||
| Accounts payable | 1,925,000 | |||
| Accrued liabilities | 9,877,000 | |||
| Debt | ||||
| Deferred compensation liability | ||||
| Due to related parties | 15,000 | |||
| Total current liabilities: | 11,817,000 | |||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 13,534,000 | |||
| Long-term debt, excluding current maturities | 13,534,000 | |||
| Liabilities, other than long-term debt | ||||
| Deferred compensation liability, classified | ||||
| Due to related parties | ||||
| Operating lease, liability | ✕ | |||
| Total noncurrent liabilities: | 13,534,000 | |||
| Total liabilities: | 25,351,000 | |||
| Equity | ||||
| Equity, attributable to parent | 74,770,000 | |||
| Common stock | 1,000 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (1,000) | |||
| Additional paid in capital | 250,032,000 | |||
| Accumulated other comprehensive income | 269,000 | |||
| Accumulated deficit | (175,531,000) | |||
| Total equity: | 74,770,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 100,121,000 | |||
Income Statement (P&L) (USD)
| 3/31/2020 | 3/31/2019 | ||
|---|---|---|---|
| Operating expenses | (110,783,000) | ||
| Operating loss: | (110,783,000) | ||
| Nonoperating expense (Other Nonoperating expense) | (257,000) | ||
| Interest and debt expense | |||
| Loss from continuing operations before equity method investments, income taxes: | (111,040,000) | ||
| Other undisclosed loss from continuing operations before income taxes | (259,000) | ||
| Loss from continuing operations before income taxes: | (111,299,000) | ||
| Income tax expense | (47,000) | ||
| Loss from continuing operations: | (111,346,000) | ||
| Loss before gain (loss) on sale of properties: | (111,346,000) | ||
| Net loss available to common stockholders, diluted: | (111,346,000) | ||
Comprehensive Income (USD)
| 3/31/2020 | 3/31/2019 | ||
|---|---|---|---|
| Net loss: | (111,346,000) | ||
| Comprehensive loss: | (111,346,000) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 262,000 | ||
| Comprehensive loss, net of tax, attributable to parent: | (111,084,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.